252 related articles for article (PubMed ID: 35492312)
1. Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan.
Maeda H; Ng DB
Front Med (Lausanne); 2022; 9():864960. PubMed ID: 35492312
[TBL] [Abstract][Full Text] [Related]
2. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
[TBL] [Abstract][Full Text] [Related]
4. Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission.
Bando H; Misumi T; Sakamoto Y; Takeda Y; Nakamura Y; Mizuguchi K; Aoyagi Y; Miki I; Kuroda T; Kasai R; Suzuki T; Yoshino T; Ohtsu A
Clin Colorectal Cancer; 2024 Jun; 23(2):111-117. PubMed ID: 38679555
[TBL] [Abstract][Full Text] [Related]
5. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
Lee H; Ahn HS; Kwon S; Kang HY; Han E
Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
Vaghela S; Tanni KA; Banerjee G; Sikirica V
Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
[TBL] [Abstract][Full Text] [Related]
7. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Hiramatsu K; Barrett A; Miyata Y;
Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
[TBL] [Abstract][Full Text] [Related]
8. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
[TBL] [Abstract][Full Text] [Related]
9. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
10. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
11. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
12. Current status of real-world big data research in the cardiovascular field in Japan.
Tonegawa-Kuji R; Kanaoka K; Iwanaga Y
J Cardiol; 2023 Mar; 81(3):307-315. PubMed ID: 36126909
[TBL] [Abstract][Full Text] [Related]
13. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
Sievers H; Joos A; Hiligsmann M
Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
[TBL] [Abstract][Full Text] [Related]
14. Real-World Evidence: A Primer.
Dang A
Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
16. The use of real-world data/evidence in regulatory submissions.
Song F; Zang C; Ma X; Hu S; Sun Q; Chow SC; Sun H
Contemp Clin Trials; 2021 Oct; 109():106521. PubMed ID: 34339865
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
[TBL] [Abstract][Full Text] [Related]
18. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
Li P; Wang S; Chen Y
Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
[TBL] [Abstract][Full Text] [Related]
19. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.
Facile R; Muhlbradt EE; Gong M; Li Q; Popat V; Pétavy F; Cornet R; Ruan Y; Koide D; Saito TI; Hume S; Rockhold F; Bao W; Dubman S; Jauregui Wurst B
JMIR Med Inform; 2022 Jan; 10(1):e30363. PubMed ID: 35084343
[TBL] [Abstract][Full Text] [Related]
20. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
Timbie JW; Kim AY; Concannon TW
Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]